Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of license costs payable.

+ References

No definition available.

+ Details

Name:	zura_AccruedLicenseCosts
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payment to be made annually under the terms of agreement.

+ References

No definition available.

+ Details

Name:	zura_AnnualMilestonePaymentDueAndPayable
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the maximum amount of development and regulatory milestone payments based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products") in asset acquisition.

+ References

No definition available.

+ Details

Name:	zura_AssetAcquisitionConsiderationMaximumDevelopmentAndRegulatoryMilestonePaymentsBasedOnRespectiveThresholdsOfNetSalesOfProducts
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum percentage of payment of annual earned royalty at a marginal royalty rate.

+ References

No definition available.

+ Details

Name:	zura_AssetAcquisitionConsiderationMaximumPercentageOfPaymentOfAnnualEarnedRoyaltyAtMarginalRoyaltyRate
Namespace Prefix:	zura_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount of sales milestone payments based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products") in asset acquisition.

+ References

No definition available.

+ Details

Name:	zura_AssetAcquisitionConsiderationMaximumSalesMilestonePaymentsBasedOnRespectiveThresholdsOfNetSalesOfProducts
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of contingent payments due.

+ References

No definition available.

+ Details

Name:	zura_ContingentPaymentDue
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone Payment, Upfront Fee

+ References

No definition available.

+ Details

Name:	zura_MilestonePaymentUpfrontFee
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The minimum net proceeds from sale of assets for one-time milestone payment.

+ References

No definition available.

+ Details

Name:	zura_MinimumNetProceedsFromSaleOfAssetsForOneTimeMilestonePayment
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The one-time milestone payment on achievement of conditions.

+ References

No definition available.

+ Details

Name:	zura_OneTimeMilestonePaymentOnAchievementOfConditions
Namespace Prefix:	zura_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payment For The Product On Net Sales, Percentage

+ References

No definition available.

+ Details

Name:	zura_PaymentForTheProductOnNetSalesPercentage
Namespace Prefix:	zura_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Upfront Fee Payment Period

+ References

No definition available.

+ Details

Name:	zura_UpfrontFeePaymentPeriod
Namespace Prefix:	zura_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=zura_AnthorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zura_LicenseAgreementWithLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zura_LonzaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zura_WuxiBiologicsLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=zura_AthanorLetterAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=zura_LicenseAgreementAndSeriesA1SubscriptionAndShareholdersAgreementWithPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Narrative (Details) - USD ($)			3 Months Ended
License Agreements - Narrative (Details) - USD ($)	Dec. 29, 2025	Mar. 22, 2022	Dec. 31, 2025	Jun. 30, 2026	Dec. 08, 2022
Anthor
License Agreements
Percentage of net sales	2.00%
License agreement with Lilly
License Agreements
Maximum amount of development and regulatory milestone payments					$ 155,000,000.0
Maximum amount of sales milestone payments					$ 440,000,000.0
Contingent payments due				$ 0
Lonza milestone payment
License Agreements
Annual milestone payment, due and payable			$ 400,000
Wuxi Biologics License
License Agreements
Amount of license costs payable				$ 0
Athanor Letter Agreement \| Anthor
License Agreements
Athanor agreement, upfront fee	$ 7,300,000
Upfront fee payment period	30 days
One-time milestone payment on achievement of conditions	$ 25,000,000.0
Minimum net proceeds from sale of assets for one-time milestone payment	500,000,000.0
Athanor Letter Agreement \| Anthor \| Common Class A
License Agreements
Stock issued during period, value, new issues (in shares)	$ 8,657,402
Agreement with Pfizer
License Agreements
Maximum amount of development and regulatory milestone payments		$ 69,000,000.0
Maximum amount of sales milestone payments		$ 525,000,000.0
Maximum annual earned royalty at a marginal royalty rate		20.00%